by Michael May | Aug 30, 2016
Michael May is President and CEO of CCRM, a leader in developing and commercializing regenerative medicine, cell and gene therapy technologies, Michael Rudnicki is Scientific Director and CEO of Stem Cell Network, with a mandate to translate stem cell research into...
by David Kent | Aug 25, 2016
One of the most memorable moments of my young scientist career was a Keystone Conference in February 2006 in Whistler, BC where I first heard Professor Shinya Yamanaka describe the successful reprogramming of a skin cell into an induced pluripotent stem cell (iPSC)....
by David Kent | Aug 2, 2016
Last week, a good friend of mine forwarded me a correspondence from the New England Journal of Medicine (NEJM). I was expecting to read about a new drug being tested in clinical trials or maybe a neat scientific perspective on leukemia biology, but what I got instead...
by David Kent | Jul 18, 2016
During the morning plenary session on the final day of ISSCR, we were treated to a delightful mix of basic and translational science as well as a riveting public policy lecture from Alta Charo. The session was all about disease modeling and stem cells and the...
by David Kent | May 31, 2016
Throughout the last decade, I have undertaken research in the stem cell field in two countries (Canada and the United Kingdom) and while my work has never involved the ethically contentious human embryonic stem (ES) cell lines, I have interacted with dozens of...
Comments